SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-244725
Filing Date
2021-08-12
Accepted
2021-08-12 16:23:08
Documents
14
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d186207d8k.htm   iXBRL 8-K 25583
2 EX-99.1 d186207dex991.htm EX-99.1 67296
6 GRAPHIC g186207g0812083824973.jpg GRAPHIC 6686
  Complete submission text file 0001193125-21-244725.txt   234608

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tpst-20210812.xsd EX-101.SCH 2916
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20210812_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20210812_pre.xml EX-101.PRE 11424
7 EXTRACTED XBRL INSTANCE DOCUMENT d186207d8k_htm.xml XML 3422
Mailing Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 211167911
SIC: 2834 Pharmaceutical Preparations